X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline
Methodological detailsinternational working group, GRADE methodology, 2 systematic reviews and narrative reviews
- International working group
- GRADE methodology
- 2 systematic reviews and narrative reviews
Recommendations
As issued by the authors
- strong recommendation, GRADEd
In adults with X-linked hypophosphatemia (XLH) and fractures or pseudofractures, burosumab is recommended over no therapy
- conditional recommendation, GRADEd
Burosumab is suggested as the preferred treatment compared to conventional therapy in the absence of fractures or pseudofractures
- Non-GRADEd recommendation
If burosumab is not available, symptomatic adults should be treated with conventional therapy
Original publication
X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →